Team 5: Atherothrombotic Disease in Heart and Brain

Group leader: Gabriel STEG

ClinicalresearchTeam 5 “Translational research on cardio- and cerebrovascular disease” started with an innovative collaboration of cardiologists and neurologists (formerly within the “clinical research on atherothrombosis” team) implemented by basic science researchers, coming from the former team on “Vascular Remodelling”. Our projects are focussed on 1/ international clinical trials assessing medical strategies and new therapies in coronary artery disease and cerebrovascular disease, particularly acute coronary syndromes and stroke, and 2/ on translational research aiming to uncover new biological markers of atherothrombosis in humans as a basis for new diagnostic/theranostic tools, but also for developing new therapeutic tools (in particular HDL-based therapies).

There is a dire need for therapies to help address the cardiovascular consequences of the diabetes and obesity epidemic. While important, this is not limited to the development of more potent and safer agents to prevent thrombosis, stabilize or prevent atherosclerosis, or treat hyperglycemia. The potential hazards (on cardiovascular mortality) of aggressive management of hyperglycemia have emphasized the need to fully assess the cardiovascular impact of antidiabetic drugs. Recent clinical trials also underlined the importance of rigorous evaluation of the clinical effectiveness of routine therapeutic strategies. Future treatments will need to demonstrate safety and cost-effectiveness in addition to efficacy. Our aim is to focus on new, effective, safe, affordable and easily implementable therapeutic strategies for atherothrombosis and diabetes.

Link to the Group on “Eicosanoids & Vascular Pharmacology”

Family name
First name
Position
Tel
Email
ABDELAZEEMHebaDoctorant01.40.25.75.29heba.muhammad@hotmail.com
ABERGELHélèneAHU01.57.27.53.57helene.abergel@aphp.fr
AMARENCOPierrePUPH101.40.25.87.25pierre.amarenco@aphp.fr
AMGOUDYasmineDoctorant140257529yasmineamgoud@gmailcom
BOUFFARDCatherineAHUcatherine.bouffard@aphp.fr
BOUHADOUNAmelDoctorant01.40.25.75.29amelbouhadoun@gmail.com
CIMADEVILLAClairePHclaire.cimadevilla@aphp.fr
DUCROCQGregoryPHgregory.ducrocq@aphp.fr
ELBEZYedidAutre_ECyedid.elbez@aphp.fr
FARNOUDRezaIR01.57.27.53.52reza.farnoud@bch.aphp.fr
FELDMANLaurentPUPH101.40.25.66.01laurent.feldman@aphp.fr
FUENTESAxelleaxelle.fuentes@gmail.com
JULIARDJean-MichelPH01.40.25.85.21jean-michel.juliard@aphp.fr
LAVALLEEPhilippaMCUPH01.40.25.70.33philippalavallee@yahoo.fr
LESECHEGuyPUPH1guy.leseche@aphp.fr
LONGROISDanPUPH101.40.25.74.27dan.longrois@aphp.fr
MANISalmaDoctorant140257529selmamany@yahoo.fr
MESEGUER GANCEDOElenaPH01.40.25.74.90elena.meseguer@aphp.fr
MSAKNIWidedmsakni_wided@yahoo.fr
NGUYENCarolineCCA01.40.25.83.53caroline.nguyen@aphp.fr
NORELXavierIE01.40.25.75.29xnorel@hotmail.com
PICARDFabienDoctorant
POPOVICBatricDoctorant
SIMONTabassomePUPHtabassome.simon@sat.aphp.fr
SORBETSEmmanuelPHemmanuel.sorbets@aphp.fr
SPIELERJean-FrançoisMCF01.40.25.87.28jean-francois.spieler@aphp.fr
STEGPhilippe GabrielPUPH101.40.25.73.25gabriel.steg@aphp.fr
TOUBOULPierre-JeanPUPH01.40.25.87.25pjtw@noos.fr
1.
Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM. 2019. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry 65:781–790.
1.
Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L. 2019. The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. Journal of the American College of Cardiology 73:113–114.
1.
Wang Y, Johnston SC, Bath PM, Grotta JC, Pan Y, Amarenco P, Wang Y, Simon T, Kim JS, Jeng J-S, Liu L, Lin Y, Wong KSL, Wang D, Li H. 2019. Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ (Clinical research ed) 364:l895.
1.
Tea V, Bonaca M, Chamandi C, Iliou M-C, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrières J, Schiele F, Simon T, Danchin N, Puymirat E, investigators F-M. 2019. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. European Journal of Preventive Cardiology 26:411–419.
1.
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG, Committees OO, Investigators. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation.
1.
Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C-C, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt FWA. 2019. Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
1.
Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, Moliterno D, Colombo A, Pocock S, Dangas G, Mehran R. 2019. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. The American Journal of Cardiology 123:709–716.
1.
Schiele F, Puymirat E, Ferrières J, Simon T, Fox KAA, Eikelboom J, Danchin N, investigators F-M. 2019. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International Journal of Cardiology 278:7–13.
1.
Puymirat E, Bonaca M, Iliou M-C, Tea V, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevallereau P, Taldir G, Bataille V, Ferrières J, Schiele F, Simon T, Danchin N, investigators F-M. 2019. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. Archives of Cardiovascular Diseases.
1.
Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferrières J, Schiele F, Simon T, Danchin N, investigators F-M. 2019. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clinical Cardiology 42:227–234.
1.
Parma Z, Young R, Roleder T, Marona M, Ford I, Tendera M, Steg PG, Stępińska J. 2019. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease in the CLARIFY registry versus other European countries. Polish Archives of Internal Medicine.
1.
Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG. 2019. Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 73:1362–1364.
1.
Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé M-P, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee V-V, Leiherer A, Lenzini PA, Levin D, Lyytikäinen L-P, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki M-L, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, others. 2019. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. Circulation Genomic and Precision Medicine.
1.
Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, Zhao X, Liu L, Wang D, Meng X, Wang Y, Investigators C in H-RPWANCE. 2019. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA neurology.
1.
Palmerini T, Bruno AG, Gilard M, Morice M-C, Valgimigli M, Montalescot G, Collet J-P, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW. 2019. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. Circulation Cardiovascular Interventions 12:e007541.
1.
Molina CA, Johnston SC, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Knutsson M, Minematsu K, Röther J, Wang Y, Wong KSL, Committee SS, Investigators. 2019. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke 50:675–682.
1.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. 2019. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal 40:1553–1562.
1.
Naccache J-M, Montil M, Cadranel J, Cachanado M, Cottin V, Crestani B, Valeyre D, Wallaert B, Simon T, Nunes H. 2019. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC pulmonary medicine 19:75.
1.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. 2019. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal 212:13–22.
1.
Kotseva K, Gerlier L, Sidelnikov E, Kutikova L, Lamotte M, Amarenco P, Annemans L. 2019. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. European Journal of Preventive Cardiology 2047487319834770.
1.
Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2019. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovascular interventions 12:983–992.
1.
Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Investigators T. 2019. The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. International Journal of Stroke: Official Journal of the International Stroke Society 1747493019830307.
1.
Gonçalves E, Bonduelle O, Soria A, Loulergue P, Rousseau A, Cachanado M, Bonnabau H, Thiebaut R, Tchitchek N, Behillil S, van der Werf S, Vogt A, Simon T, Launay O, Combadière B. 2019. Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. The Journal of Clinical Investigation 130.
1.
Freund Y, Gorlicki J, Cachanado M, Salhi S, Lemaître V, Simon T, Mebazaa A. 2019. Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial. Trials 20:95.
1.
Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy F-X, Ricci L, Steg PG. 2019. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice. Archives of Cardiovascular Diseases.
1.
Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2019. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 12:e007133.
1.
Easton JD, Denison H, Evans SR, Knutsson M, Amarenco P, Albers GW, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC, Committee SS, Investigators. 2019. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. International Journal of Stroke: Official Journal of the International Stroke Society 1747493019851282.
1.
Danchin N, Puymirat E, Latremouille C, Simon T. 2019. Coronary artery bypass surgery: The starting point of a long medical journey. European Journal of Preventive Cardiology 26:398–400.
1.
Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong M-K, Kim H-S, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, Investigators P-DS. 2019. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. Journal of the American College of Cardiology 73:741–754.
1.
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG. 2019. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology 21:421–427.
1.
Coleman JJ, Samer C, Zeitlinger M, van Agtmael M, Rongen GA, Marquet P, Simon T, Singer D, Manolopoulos VG, Böttiger Y. 2019. The European Association for Clinical Pharmacology and Therapeutics-25 years’ young and going strong. European Journal of Clinical Pharmacology 75:743–750.
1.
Chichareon P, Modolo R, van Klaveren D, Takahashi K, Kogame N, Chang C-C, Katagiri Y, Tomaniak M, Asano T, Spitzer E, Buszman P, Prokopczuk J, Fath-Ordoubadi F, Buysschaert I, Anderson R, Oldroyd KG, Merkely B, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Onuma Y, Serruys PW. 2019. Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology 286:43–50.
1.
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, Steg PG, Committee TS. 2019. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology 42:498–505.
1.
Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A. 2019. Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study. The American Journal of Medicine.
1.
Bataille V, Ferrières J, Danchin N, Puymirat E, Zeller M, Simon T, Carrié D. 2019. Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. European Heart Journal Acute Cardiovascular Care 8:218–230.
1.
Bassiouni W, Daabees T, Norel X, Senbel AM. 2019. Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist. Naunyn-Schmiedeberg’s Archives of Pharmacology 392:437–450.
1.
Bassiouni W, Daabees T, Louedec L, Norel X, Senbel A. 2019. Evaluation of some prostaglandins modulators on rat corpus cavernosum in-vitro: Is relaxation negatively affected by COX-inhibitors? Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 111:1458–1466.
1.
Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. 2019. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circulation Cardiovascular Quality and Outcomes 12:e004945.
1.
Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ. 2019. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. European Heart Journal Cardiovascular Pharmacotherapy 5:70–79.
1.
Allard M, Puszkiel A, Conti F, Chevillard L, Kamar N, Noé G, White-Koning M, Thomas-Schoemann A, Simon T, Vidal M, Calmus Y, Blanchet B. 2019. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. Clinical Therapeutics 41:882-896.e3.
1.
Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD, Investigators P. 2019. Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 213:57–65.
1.
Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL. 2019. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circulation Cardiovascular Interventions 12:e007445.
1.
Abboud H, Monteiro Tavares L, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P. 2019. Impact of Low Ankle-Brachial Index on the Risk of Recurrent Vascular Events. Stroke 50:853–858.
1.
Zeng X, Lincoff AM, Schulz-Schüpke S, Steg PG, Elbez Y, Mehran R, Stone GW, McAndrew T, Lin J, Zhang X, Shi W, Lei H, Jing Z, Huang W. 2018. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. Journal of Cardiology 71:494–504.
1.
Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC, Committee SS, Investigators. 2018. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke 49:1678–1685.
1.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, Investigators GL. 2018. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet (London, England) 392:940–949.
1.
Vidal-Petiot E, Elbez Y, Lüscher TF, Fox KM, Steg PG. 2018. The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients. European Heart Journal 39:4040–4041.
1.
Vogin G, Merlin J-L, Rousseau A, Peiffert D, Harlé A, Husson M, Hajj LE, Levitchi M, Simon T, Simon J-M. 2018. Absence of correlation between radiation-induced CD8 T-lymphocyte apoptosis and sequelae in patients with prostate cancer accidentally overexposed to radiation. Oncotarget 9:32680–32689.
1.
Villeret B, Dieu A, Straube M, Solhonne B, Miklavc P, Hamadi S, Le Borgne R, Mailleux A, Norel X, Aerts J, Diallo D, Rouzet F, Dietl P, Sallenave J-M, Garcia-Verdugo I. 2018. Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial Cells. ACS nano 12:1188–1202.
1.
Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG. 2018. Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal 39:3855–3863.